Emerging data suggest Retatru tide , a dual agonist targeting both the gut-brain axis and GIP , appears to offer a notable advancement for obesity management . Initial clinical tests have shown substantial decreases in visceral tissue, potentially exceeding other weight-loss therapies . However , further assessment is necessary to completely determ